containing 2 zinc fingers in tandem, which has been implicated in sarcomere assembly (Gueneau, et al., 2009; McGrath, et al., 2006) .
Emerin and lamin A/C are thought to have a close functional relationship, even though the phenotypes caused by EMD and LMNA mutations are clinically different Meune, et al., 2006) . In fact, direct interaction between emerin and lamin A has been demonstrated by multiple experimental techniques (Clements, et al., 2000; Lee, et al., 2001) and emerin localization has been shown to be affected by mutant lamin A (Holt, et al., 2003) .
LMNA mutations have also been detected in patients with autosomal dominant limb-girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B, MIM# 159001) . While the clinical phenotype of LGMD1B overlaps with EDMD, there are differences, for example, LGMD1B is characterized by slowly progressive pelvic girdle weakness, with a sparing of the lower leg muscles. In addition, contractures and cardiac disturbances tend to occur later in life in LGMD1B, compared to EDMD patients .
In addition to EDMD, LGMD1B, L-CMD and isolated dilated cardiomyopathy and conduction-system disease (CMD1A, MIM# 115200) (Fatkin, et al., 1999 ) that primarily affect striated muscle, 'laminopathies' also affect other tissues. Such laminopathies include Dunningan-type familial partial lipodystrophy (FPLD, MIM# 151660) (Hegele, et al., 2000; Shackleton, et al., 2000; Speckman, et al., 2000) , autosomal recessive Charcot-Marie-Tooth
Disorder Type 2B1 (CMT2B1, MIM# 605588) (De Sandre-Giovannoli, et al., 2002) , mandibuloacral dysplasia (MAD, MIM# 248370) (Novelli, et al., 2002; Shen, et al., 2003) ,
Hutchinson-Gilford progeria syndrome (HGPS, MIM# 176670) (De Sandre-Giovannoli, et al., 2003; Eriksson, et al., 2003) , and autosomal dominant atypical Werner's syndrome (Chen, et al., 2003) . In addition, both intra-familial and inter-familial variability of phenotypes associated with LMNA mutations is a common feature (Shen, et al., 2003; Simha, et al., 2003; Speckman, et al., 2000; Vytopil, et al., 2002) .
A clear genotype-phenotype correlation has not been identified for most laminopathies, although HGPS tends to correlate with C-terminal splicing defects, while other conditions (i.e. MAD, WRN and CMT2B1) result from 'hot spot' missense mutations. For other laminopathies including EDMD, the pathogenic LMNA mutations are distributed throughout the gene (Scharner, et al., 2010) . The LMNA gene contains 12 exons and encodes both lamin A and C by alternative splicing, both sharing the first 566 amino acids (Lin and Worman, 1993) . In addition to their role in the nuclear lamina, lamins also interact with numerous integral proteins of the inner nuclear membrane and proteins of nuclear pore complexes (Schirmer and Foisner, 2007) , orchestrating a number of cellular and molecular processes including nuclear envelope assembly, maintenance of nuclear architecture, DNA synthesis, chromatin organization, gene transcription, cell cycle progression, cell differentiation and migration and response to DNA damage (Broers, et al., 2006; Prokocimer, et al., 2009; Verstraeten, et al., 2007) , processes that could be differentially affected by specific mutations.
This report describes novel and recurrent LMNA mutations identified in 50 patients referred for clinical testing for a suspected diagnosis of EDMD or LGMD in the USA and Canada. This is also the first report of the distribution of LMNA mutations from a large patient cohort from outside Europe, and augments the EDMD mutation database by ~6%. Importantly, amongst these were 15 novel pathogenic LMNA mutations that include eight missense 
Material and Methods

Patients
The 255 patients reported in this manuscript were referred to either the DNA Diagnostic Laboratory at Carolinas Medical Center (1996) (1997) (1998) (1999) (2000) (2001) 
DNA Isolation and Polymerase Chain Reaction
DNA extracted from peripheral blood by either standard proteinase K/phenol-chloroform extraction procedures on a 341 Nucleic Acid Extractor (Perkin-Elmer, Norwalk, CT) or using a QIamp DNA Blood Mini Kit (Qiagen, Valencia, CA). Exons 1-12 of LMNA were amplified by PCR as previously described . Primers used for the PCR reaction are listed in table 1.
Sequencing
Amplimers were extracted from agarose gel using a Gel Extraction Kit (Qiagen, Valencia, CA) and each exon sequenced directly from both strands using the Prism Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) with analysis of sequenced products on either an ABI377 or ABI3100 Genetic Analyzer. 
Retroviral expression vectors
The retroviral (RV) backbone pMSCV-puro (Clontech, Mountain View, CA) was modified to replace the puromycin selection gene with eGFP, to create pMSCV-IRES-eGFP, which served as the RV control vector (Zammit, et al., 2006) . Wild type (Motsch, et al., 2005) and four mutant human lamin A pEGFP-C1 cDNAs (R25P, R249W, N456I and R541P) were sub-cloned into pMSCV-IRES-eGFP to generate control pMSCV-laminA-IRES-eGFP and
pMSCV-laminA-R25P-IRES-eGFP, pMSCV-laminA-R249W-IRES-eGFP, pMSCV-laminA-
N456I-IRES-eGFP and pMSCV-laminA-R541P-IRES-eGFP, producing either wildtype lamin
A as a control, or mutant lamin A species, as a bicistronic message with eGFP ( Figure 2C ).
Retroviral constructs, together with an ecotropic packaging plasmid, were transiently cotransfected into 293T cells to produce non-replicating retrovirus and the supernatant harvested 48, 60 and 72 hours later.
Cell Culture and Retroviral infection
C2C12 mouse myoblast cells were grown and maintained in DMEM-Glutamax (Invitrogen, Paisley, UK) supplemented with 10% FBS (PAA, Somerset, UK) and 1%
Penicillin/Streptomycin (Sigma, Dorset, UK). A total of 20,000 C2C12 cells were plated into one well of a 6-well plate and exposed to retroviral supernatant (diluted 1:5 in growth F o r P e e r R e v i e w 9 medium supplemented with 4µg/mL polybrene) for at least 12 hours, before they were analyzed at least 24 hours later.
Morphometric Analysis
To quantify the morphological abnormalities of nuclei such as elongation or lobulation, we measured the perimeter and the area of at least 120 nuclei from 3 independent experiments and calculated the nuclear roundness or contour ratio (4π area/circumference 2 ) (Goldman, et al., 2004) . The contour ratio of a circle is 1 and the value gets smaller with an increased degree of lobulation. Micrographs of infected C2C12 cells stained for lamin B were analyzed using the NIH ImageJ software (http://rsbweb.nih.gov/ij/). To calculate the perimeter and area of the nuclei, they were outlined using the polygon selection tool and measured with ImageJ. A two-tailed Student's t-test was used to calculate the statistical significance of the result.
Immunostaining
Cells were fixed with 4% paraformaldehyde (PFA) for 10 minutes, permeabilized with 0.5% Triton X-100 in PBS for 10 minutes and blocked with 5% normal goat serum and 5% normal swine serum (or 5% horse serum and 5% normal swine serum when primary antibodies raised in goat were used) in PBS/0.025% Tween20 for 1 hour at room temperature. After incubation with primary antibody in 1% serum (goat anti-lamin A C20 1:100, goat anti-lamin A/C N18 1:200, goat anti-lamin B (recognises all forms) M20 1:200 (Santa Cruz Biotechnology, Santa Cruz, CA); rabbit anti-emerin AP8 1:100 (Ellis, et al., 1998) ; rabbit anti-GFP 1:500 (Molecular Probes, Eugene, OR) and mouse anti-GFP 7.1&13.1 1:100 (Roche, Mannheim, Germany)), the cells were washed and exposed to fluorescently coupled secondary antibodies (Alexa Fluor -Molecular Probes, Eugene, OR) at a concentration of 
Fluorescence intensity measurement
Representative nuclei stained for DAPI, lamin A and lamin B respectively were analyzed using the "Plot Profile" tool in ImageJ. The x, y coordinates were imported in MS Excel to compile the histogram.
Western Blot
Harvested cells were re-suspended in suspension buffer (100mM NaCl, 10mM TrisHCl pH7.5, 1mM EDTA) supplemented with proteinase inhibitors and lysed in loading buffer (Laemmli, 1970) . The protein concentration was determined with the Bio-Rad DC Protein
Assay based on the Lowry method (Lowry, et al., 1951) . Samples were immunoblotted with the following antibodies: goat anti-lamin A/C N18 1:1000 (Santa Cruz Biotechnology, Santa
Cruz, CA), rabbit anti-GFP 1:2000 (Molecular Probes, Eugene, OR), mouse anti β-tubulin 1:1000 (DSHB, Iowa City, IA), and then probed with HRP-conjugated secondary antibodies (ECL™ sheep anti mouse or rabbit 1:5000, GE Healthcare, Uppsala, Sweden; sheep anti goat SO84 1:5000, Abcam, Cambridge, UK) and developed using ECL from GE Healthcare. Band intensity was quantified using ImageJ. 
Results
Clinical and genetic information on 50 patients
This is the first report on the distribution of LMNA mutations from a large patient cohort from the USA and Canada. Among the 255 referrals, 23 patients (9.0%) were found to possess EMD gene mutations (manuscript in preparation) and 61 individuals (23.9%) were found to have LMNA mutations. Clinical and genetic information on 11 of the patients with LMNA mutations has been published previously ). The mutations identified in the remaining 50 patients and their clinical information are presented in Tables 2   and 3 .
Amongst the 50 individuals found to carry a LMNA mutation, 37 different mutations (in 36 patients) were detected, scattered throughout the gene ( Figure 1A and Table 2 and 3). The majority of LMNA mutations identified here are missense mutations (27/37; 73.0%), with an additional 2 mutations being small in-frame insertions or deletions (2/37; 5.4%). Seven mutations were found to be deleterious mutations at conserved donor or acceptor splice site sequences (5/37; 13.5%) or silent mutations (2/37; 5.4%). The final mutation in patient 2974 was the only frame shift mutation, presumably encoding both truncated lamin A and lamin C protein species (1/37; 2.7%). This patient had a predominantly cardiac phenotype with only mild skeletal muscle weakness developing at age 50. These results are consistent with the phenotypes of other patients found to possess truncating mutations (Benedetti, et al., 2007) .
The most common previously reported LMNA mutation, c.1357C>T (p.R453W), was also the most frequent in our study group, being found in 6 (12.0%) of the patients. Two mutations were found to be confined to the lamin A protein, p.G602S and p.R644C, suggesting that alterations in the far C-terminus of the lamin A protein alone is sufficient to cause EDMD2. we have information (p.R453W), 2 cases were familial and 3 cases were sporadic. DNA analysis was only performed on the family members of 3 cases classed as sporadic (patients 6537, 3734, and 778), which confirmed the de novo origin of mutations in these individuals.
It is possible of course, that apparently sporadic cases may have relatives who are currently asymptomatic gene mutation carriers.
Novel pathogenic LMNA mutations
Of these 37 LMNA mutations, 15 are novel pathogenic LMNA mutations (highlighted in red in Figure 1A and B and Having described pathogenic LMNA mutations in patients, we next sought to gain insight into the effects of several mutant human lamin A species on myogenic cells. We chose four mutations from this (p.R249W and p.R541P) and our previous study (p.R25P and p.N456I) ) that span the LMNA gene and affect different domains of the protein.
Effects of lamin A mutants on myogenic cells
The majority of pathogenic lamin A mutations are dominant, with usually only one allele being affected in patients. This suggests that in cases that are not caused by haploinsufficiency, the amount of mutated protein that is necessary to create a phenotype is relatively small. Importantly, patient myoblasts are not readily available and a commonly used DNA delivery method is cell transfection, which results in dramatic over-expression (up to 25 fold) of mutant lamin A (Bechert, et al., 2003) .
Retroviral infection is efficient in mouse C2C12 myogenic cells with an infection rate of >98% routinely obtained (data not shown). Retroviral-mediated constitutive expression of
wild-type lamin A clearly shows the co-expression of lamin A and eGFP, with cells with higher levels of eGFP generally also expressing higher levels of lamin A ( Figure 2A ). In addition to efficiently targeting >98% cells, retroviral-mediated constitutive expression also has the advantage that the levels of exogenous proteins are generally only moderately elevated compared to endogenous proteins. Western blot analysis confirmed increased levels of exogenous wild type and mutant lamin A was only on average 1.3-1.7 fold higher than controls ( Figure 2B ) resembling a more physiological condition. Endogenous expression level of lamin C was not affected ( Figure 2B ). We observed large differences in nuclear size depending on the lamin variant expressed.
The presence of lamin A-R25P and lamin A-R249W results in abnormal nuclear morphology
While a small increase in the nuclear cross-sectional area was observed in cells treated with the RV control, the average nuclear size was further significantly increased in the presence of lamin A-R25P (29% increase) and lamin A-R249W (34% increase) compared to lamin Awild type infected cells ( Figure 2D ). Constitutive expression of lamin A-wild type did not have an effect on nuclear size. The dramatic increase in nuclear size coincides with changes in nuclear morphology. Normal ovoid nuclear morphology was observed when cells were (0.85±0.007), reflecting these nuclear distortions ( Figure 2E ). Changes in both nuclear size and contour ratio occurred concomitantly. This effect was mutation specific however, since the presence of lamin A-N456I or lamin A-R541P did not alter nuclear size or shape.
Mutant lamin A protein species are mislocalised in the nucleus
Abnormalities in mutant lamin A protein distribution were also observed ( Figure 3 and 4A-C). Although all the mutant lamin A proteins were present to some degree at the nuclear periphery, there was frequent disorganisation of the lattice, with evidence of lamin A capping, particularly in lamin A-R25P and lamin A-R249W-expressing nuclei (lamin A mislocalization is shown by arrows in Figure 3 ). There were also more lamin A-positive nuclear speckles present, with a greater size distribution compared with cells expressing lamin A-wild type. Prominent lamin A speckles distributed throughout the nucleus were particularly evident in many cells expressing the lamin A-N456I and lamin A-R541P mutant proteins, (lamin A-N456I, 25.9%±4.0%; lamin A-R541P, 9.0%±3.5%) than with the other Nuclear lamin A foci were not analyzed in cells infected with RV control because the fixation protocol used to preserve cellular morphology resulted in endogenous mouse lamin A being weakly detected (Figure 3 ), compared to the robust immunostaining to the human lamin A species encoded by RVs.
Endogenous lamin B mis-localization in the presence of lamin A-R25P and R249W
To investigate whether other endogenous nuclear envelope components were mislocalised in the presence of the mutant lamin A proteins, we analyzed the expression of several
components of the nuclear envelope by immunocytochemistry (Figures 3 and 4D-F). Lamin
A and C directly bind emerin in vitro (Vaughan, et al., 2001 ) and have been shown to colocalize with mutant lamin A (Ostlund, et al., 2001 ). We therefore determined if the expression of our constructs had an effect on emerin localization, and if lamin A-N456I in particular, could cause nuclear foci that strongly immunostain for emerin. However, none of the lamin A mutants induced nuclear foci that contained emerin, confirming previous descriptions (Capanni, et al., 2003; Muchir, et al., 2004) (Figure 3 ). F-actin staining by standard immunofluorescence microscopy appeared normal, except in cells expressing the p.R25P mutation, where fewer stress fibres were observed (Figure 3 ).
The localization of lamin B however was changed by the expression of two mutant lamins. In nuclei of cells expressing lamin A-R25P and lamin A-R249W, B-type lamins were lost from one or more poles in some cells ( Figure. 3, arrowed and Figure 4D ), which was particularly 
Discussion
In this study we report 16 patients with novel, and 34 patients with recurring LMNA mutations, increasing the known LMNA mutation database by ~5.9% (The Universal Mutation Database (UMD)). Since laminopathies are rare diseases, this significant increase in patient data will hopefully aid genotype/phenotype correlations.
Variable expressivity of the EDMD phenotype is noted in many families illustrating the importance of the genetic background for clinical presentation. One example of highly variable expressivity in EDMD2 is demonstrated by the family of patient 7309, found to be heterozygous for the common p.R453W lamin A/C mutation. The proband was initially diagnosed with a mild form of LGMD1B at age 6, and at age 26, he had mild proximal muscle weakness, contractures and cardiac involvement. The probands father died of heart failure at age 61, at which time he had neck and elbow contractures, but minimal, if any, muscle weakness. The proband's paternal grandmother was not considered to be affected with EDMD until an autopsy performed at age 88 revealed a skeletal muscle myopathy consistent with this disorder, but a cardiac muscle biopsy exhibited no significant pathology.
Another example of the phenomenon of variable expressivity is demonstrated by patient 33, who was found to be heterozygous for an intron 4 splice junction mutation. Whilst both patient 33 and his sister were known to be affected with EDMD2 upon referral for genetic testing, neither of their parents showed any clinical signs of this disorder. Molecular testing indicated that their father carried the splice junction mutation and shortly after receiving this information, presented with cardiac arrhythmia. We previously reported patient 1325 who is heterozygous for both p.E358K and p.R624H
mutations . We hypothesized that the compound heterozygous mutations found in this patient may account for her particularly severe phenotype, with the lamin Aspecific mutation being either recessive or dominant with incomplete penetrance, as it was detected in her clinically unaffected father. Of note, three other patients in this study were found to be heterozygous for just the p.E358K mutation, and all appear to be severely affected with EDMD, making the role of the second, lamin A-specific mutation, in patient 1325 unclear. In this study, 2 compound heterozygous patients were found, both presenting with an early onset phenotype (marked by # in table 2). Patient 6388, with a severe form of EDMD, was compound heterozygous for c.IVS-1G>T and p.D461Y, two mutations that have been described before in a patient with early onset EDMD (Bakay, et al., 2006) . A second severely affected patient (patient 3) was also found to be a compound heterozygote carrying p.R249W and p.R644C mutations. Interestingly, our study population included patients carrying each of these sequence alterations individually, with patient 8281 being heterozygous for the p.R249W alteration and patient 51 being heterozygous for the lamin Aspecific p.R644C mutation. As the two latter patients with single mutations are affected with early age-of-onset disease, both of these mutations appear to act in a dominant fashion. This (Benedetti, et al., 2007; Bonne, et al., 1999; Fokkema, et al., 2005; Muchir, et al., 2004; Onishi, et al., 2002; Raffaele Di Barletta, et al., 2000; van der Kooi, et al., 2002; Vytopil, et al., 2003 ) with R644C causing a large variety of phenotypes including EDMD Csoka, et al., 2004; Mercuri, et al., 2005; Rankin, et al., 2008) . We conclude that additional mechanisms must contribute to the disease severity at presentation such as modifier genes or digenism. Patients with mutations in both EMD and LMNA genes present with a more severe are not conserved in evolution. Interestingly, both non-conserved residues are mutated to a proline and located adjacent to pathogenic residues. These are p.R190, associated with DCM when mutated to Trp or Gln (Perrot, et al., 2009; Sylvius, et al., 2005) , and p.Y267, associated with EDMD and DCM when mutated to His or Cys (Carboni, et al., 2008; Vytopil, et al., 2003) . Proline is not found in the centre of a straight alpha-helix, due to its helix breaking attributes (Richardson and Richardson, 1988) . Interestingly, 9/30 (30%) of all pathogenic, non-conserved residues in the central rod domain, are substituted to a proline.
Eight of these cause either EDMD or DCM while one (p.A57P) has been reported to cause WRN (Chen, et al., 2003) . Our data therefore confirms the assumption that the introduction of a proline is more likely to be pathogenic irrespective of amino acid conservation.
Eight patients were found to have mutations located on the exon-intron or intron-exon junctions, suggesting they may affect pre-mRNA splicing. In five (33, 7975, 1412, 6388 and 2660) , the universally conserved GT and AG di-nucleotides are affected. The majority of intronic splice site mutations published so far are associated with DCM or LGMD1B (Chrestian, et al., 2008; Otomo, et al., 2005) while others have been shown to result in EDMD (Bakay, et al., 2006) . In our study however, all patients with intronic splice site mutations presented with an EDMD phenotype ( LGMD phenotype with cardiac involvement, the first nucleotide in exon 2 is mutated to a T (c.357C>T; p.R119R) ( Figure 1A ). Such mutation-types are very rare mutational events and only one other such mutation has been described so far in the LMNA gene. It is located on the last nucleotide of exon 2 (c.513G>A; p.K171K) and was found in four patients diagnosed with LGMD1B (Todorova, et al., 2003) . mRNA analysis on these patients showed that this results in a partial skipping of the canonical 5' splice site in intron 2 and the alternative use of a cryptic GT donor site within intron 2 leading to an insertion of 15 additional amino acids between exon 2 and 3 (Todorova, et al., 2003) .
Cells isolated from patients with LMNA mutations, or cells over-expressing mutant lamin A, often display aberrant localization of nuclear envelope proteins and changes in nuclear morphology. In our study, we observe both phenomena: constitutive lamin A-R25P and lamin A-R249W expression caused severe changes in nuclear shape and size, while lamin A-N456I and lamin A-R541P resulted in nuclear lamin A-positive foci. Nuclear foci staining for lamin A are frequently described when over-expressing mutant and lamin A-wild type in vitro (Bechert, et al., 2003; Holt, et al., 2001; Ostlund, et al., 2001) . In contrast, such foci are not very common in primary cells isolated from patients with LMNA mutations (Emerson, et al., 2009; Markiewicz, et al., 2002; Muchir, et al., 2004; Taimen, et al., 2009; Vigouroux, et al., 2001; Zhang, et al., 2007) , suggesting that lamin A-positive foci formation can be (Capanni, et al., 2003; Muchir, et al., 2004) . We see similar effects using mouse C2C12 myogenic cells. Cells expressing lamin A-R25P and lamin A-R249W do not form nuclear foci staining for lamin A. However, constitutive expression of the lamin A variants with a mutation in the Ig-like fold (lamin A-N456I) and adjacent to the Ig-like fold (lamin A-R41P) induces lamin A foci formation in 25% and 10% of all infected nuclei respectively. Although nuclear foci appear to be smaller in cells infected with lamin A-R541P, these results may suggest that the molecular mechanism inducing these foci and perhaps the underlying disease mechanism, is similar for the two mutations in the tail domain of lamin A analyzed in this study.
In contrast, constitutive lamin A-R25P and lamin A-R249W expression in mouse myogenic cells caused severe changes in nuclear shape and size. Nuclear blebbing is a type of nuclear distortion commonly found in progeria and other laminopathies (Eriksson, et al., 2003; Goldman, et al., 2004; Jacob and Garg, 2006; Taimen, et al., 2009 ). Khatau et al. report that the nuclear morphology can be regulated by a perinuclear actin cap which is disrupted in cells from lmna -/-and lmna L530P/L530P mice (Khatau, et al., 2009) . To test if the abnormal nuclear morphology we observed was associated with a misarranged actin-cytoskeleton, we stained infected C2C12 cells for F-actin. However, while there were perturbed F-actin stress fibres with lamin A-R25P, as has been described previously for other mutations in patient fibroblasts (Emerson, et al., 2009) , confocal imaging did not reveal differences in the perinuclear actin cap associated with this, or any of our other mutant lamin A-species (data not shown). This suggests that there might be other factors involved in nuclear deformation in this case. One possibility of nuclear deformation is a misregulation of nesprin or other members of the LINC complex which physically connects the nuclear lamin with the cytoskeleton (Razafsky and Hodzic, 2009 ). The expression pattern of these interaction partners will be the subject of future investigations.
Interestingly, aberrant nuclear morphology in both mutants (lamin A-R25P and lamin A-R249W) is accompanied by a polar loss of lamin B expression in approximately 20-30% of nuclei. The same phenomenon has been observed by others in cells from HGPS patients with the p.E145K mutation (Taimen, et al., 2009 ) and in fibroblasts isolated from FPLD patients (Vigouroux, et al., 2001) . Mouse embryonic fibroblasts from mouse embryos homozygous for a truncated, non-functional form of lamin B1 show severely misshaped nuclei too,
suggesting that the loss of lamin B1 is a causative event for the observed nuclear lobulation (Vergnes, et al., 2004) . How mutated lamin A affects lamin B localization is unclear and if a correction of lamin B expression can restore a normal nuclear morphology remains to be determined. It would also be very interesting to see if there are any LMNA single nucleotide polymorphisms (SNPs) that can affect lamin B localization and nuclear morphology.
Generally, patient fibroblasts with mutations associated with severe forms of laminopathies such as MAD (p.L59R, p.R527C, p.R527H) (Agarwal, et al., 2008; Nguyen, et al., 2007; Novelli, et al., 2002) , WRN (p.R133L, p.L140R) (Caux, et al., 2003; Chen, et al., 2003) and FPLD (p.R439C) (Verstraeten, et al., 2009 ) all show the most profound changes in nuclear morphology. Taimen et al. have shown that nuclei of dermal fibroblast isolated from HGPS patients with the lamin A-E145K mutation show drastic changes in morphology and are severely lobulated (Taimen, et al., 2009) . It has been suggested that the underlying mechanism of the pathogenicity of HGPS causing lamin A-E145K is a disrupted filament formation (Taimen, et al., 2009 ). However, mutant lamin A variants that caused an effect on nuclear morphology in our study result in either typical EDMD2 (lamin A-R25P) or an early onset/L-CMD phenotype (lamin A-R249W), but whether they affect filament formation to differing degrees is unknown.
A-type lamins are expressed in mouse satellite cells: the resident stem cells of skeletal muscle (Gnocchi, et al., 2009) . Therefore perturbed lamin function does not only affect the myonuclei of muscle fibres, but could also compromise satellite cell-mediated muscle maintenance and repair. A disrupted nuclear morphology is likely to affect basic cellular processes, such as proliferation and differentiation of myoblasts (Gnocchi, et al., 2008) . It is generally accepted that mutations in lamin A can affect cell cycle kinetics (Emerson, et al., 2009; Johnson, et al., 2004) . Fibroblasts from HGPS patients demonstrate a decreased cell growth rate (Goldman, et al., 2004) and fibroblasts isolated from EDMD but not DCM patients have been shown to have an increase in cell proliferation (Emerson, et al., 2009 ).
However, it has also been reported that cell cycle progression is dependent on nuclear size (Roca-Cusachs, et al., 2008; Yen and Pardee, 1979) . It is therefore likely that cells expressing lamin A-R25P and lamin A-R249W show altered cell cycle progression and proliferation.
In conclusion, we describe 15 novel LMNA mutations that underlie a striated muscle phenotype, increasing the mutation spectrum by ~6%. These will contribute towards formulating more accurate genotype-phenotype correlations in the laminopathies. Our analysis of 4 LMNA mutations shows that those located in the central rod domain perturb lamin B polarization and nuclear morphology, whilst mutations in the Ig-like fold domain increase lamin A-positive nuclear foci. We conclude that although the molecular mechanisms underlying the LMNA-generated pathogenic cascade in a particular tissue, with respect to intrinsic cellular processes such as cell cycle and cell signalling etc., may be similar for a given laminopathy, the disease penetrance and clinical variability within a phenotype may 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
